Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

COPENHAGEN, Sept 13 (Reuters) - Danish drugmaker Novo Nordisk said new data showed people with type 2 diabetes experienced improvements in controlling blood sugar levels when using its diabetes drug ...

Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...

Sorry, Victoza. Novo Nordisk ($NVO) has given up on the GLP-1 drug as a treatment for Type 1 diabetes, at least for now. A blockbuster in the Type 2 form of the ...

Branded content furnished by our promotional partners. The Daily Sundial editorial staff is not involved in its production. Content does not reflect the views or opinions of the editorial staff.

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk said two patients in Japan who were being treated with its Victoza type-2 diabetes drug died from the discontinuation of their insulin treatment ...

While Novo Nordisk already holds 27% of type-2-diabetes market share, data released over the weekend may help the company to further corner this market while providing a buffer against competition.

Two products for the treatment of type 2 diabetes, insulin degludec (Tresiba) and liraglutide (Victoza), both from Danish drug firm Novo Nordisk, have this week been given positive opinions for ...

Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza. Lilly unveiled top-line ...

In a phase 3 clinical trial, liraglutide was shown to reduce the body mass index in children ages 6 to 11 with obesity, according to a study published Sept. 10 in The New England Journal of Medicine.